企業プロフィール
NextCure 株価・ニュース・カタリスト
- ティッカー:
- NXTC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
7.71 USD (-6.09%)
終値
最終更新: 2026年8月17日
12.3M USD
時価総額
株価変動の要因
As of Aug 17, 2026, NXTC closed down 6.09% at $7.71. No new same-company headline was identified in the current news window.
企業概要
Oncology Drug Development
NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches.
SIM0505
SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6 expression, including platinum-resistant ovarian cancer.
LNCB74
LNCB74 is a separate Phase 1 oncology candidate undergoing dose escalation, providing NextCure with a second clinical-stage program.
今後のカタリスト
- Phase 1 dose-escalation data for SIM0505 at ASCO 2026.
- Phase 1 dose-escalation update for LNCB74 in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。